http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104837819-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53ab8b321acdbf51b152c6ae89ec837e
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0482
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-14
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-14
filingDate 2013-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c345bdd4427757bd618c6b3846cd20c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea7d6bee3b18063d2568fba4b70f6247
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_701a6a6490c1a1d81041fe7627386c30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_200d9fd48d70a8a04cc8ffbbffcff2e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5d564df869b68da2ebe55f91e66013a
publicationDate 2015-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-104837819-A
titleOfInvention neurotensin receptor ligand
abstract The present invention relates to a compound of formula (I) or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein R is selected from hydrogen, methyl and cyclopropylmethyl; AA-COOH is selected from 2 -amino- Amino acids of 2-adamantanecarboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R2 is selected from (C 1 -C 6 )alkyl, (C 3 -C 8 ) cycloalkyl, (C 3 -C 8 ) cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C 2 -C 5 ) alkylene; R 3 , R 4 and R 5 Each and independently selected from hydrogen and (C 1 -C 4 )alkyl, provided that one of R 3 , R 4 and R 5 has the formula (II), wherein ALK' is (C 2 -C 5 )alkylene R 6 is selected from hydrogen and (C 1 -C 4 )alkyl; and R 7 is selected from H and effector moieties.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111875667-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111875667-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114341159-A
priorityDate 2012-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9833531-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5607958-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006062729-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011156557-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467360107
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467808307
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467360116

Total number of triples: 34.